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Abstract
Background: It is known from recent studies that more than 90% of human multi-exon genes are subject to
Alternative Splicing (AS), a key molecular mechanism in which multiple transcripts may be generated from a single
gene. It is widely recognized that a breakdown in AS mechanisms plays an important role in cellular differentiation
and pathologies. Polymerase Chain Reactions, microarrays and sequencing technologies have been applied to the
study of transcript diversity arising from alternative expression. Last generation Affymetrix GeneChip Human Exon
1.0 ST Arrays offer a more detailed view of the gene expression profile providing information on the AS patterns.
The exon array technology, with more than five million data points, can detect approximately one million exons,
and it allows performing analyses at both gene and exon level. In this paper we describe BEAT, an integrated user-
friendly bioinformatics framework to store, analyze and visualize exon arrays datasets. It combines a data
warehouse approach with some rigorous statistical methods for assessing the AS of genes involved in diseases.
Meta statistics are proposed as a novel approach to explore the analysis results. BEAT is available at http://beat.ba.
itb.cnr.it.
Results: BEAT is a web tool which allows uploading and analyzing exon array datasets using standard statistical
methods and an easy-to-use graphical web front-end. BEAT has been tested on a dataset with 173 samples and
tuned using new datasets of exon array experiments from 28 colorectal cancer and 26 renal cell cancer samples
produced at the Medical Genetics Unit of IRCCS Casa Sollievo della Sofferenza.
To highlight all possible AS events, alternative names, accession Ids, Gene Ontology terms and biochemical
pathways annotations are integrated with exon and gene level expression plots. The user can customize the results
choosing custom thresholds for the statistical parameters and exploiting the available clinical data of the samples
for a multivariate AS analysis.
Conclusions: Despite exon array chips being widely used for transcriptomics studies, there is a lack of analysis
tools offering advanced statistical features and requiring no programming knowledge. BEAT provides a user-friendly
platform for a comprehensive study of AS events in human diseases, displaying the analysis results with easily
interpretable and interactive tables and graphics.
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In biological complexity generation, the AS mechanism
is a major contributor to the diversity of proteome [1,2].
Although it has long been presumed that only 5% of
human genes was alternatively spliced, more recent esti-
mates - based on experimental evidence and computa-
tional approaches using ESTs mapped onto mRNA
sequences - showed a much higher rate of the phenom-
enon in human genes: the actual percentage of genes
that exhibit AS events has grown up to 95% [3-8]. The
AS mechanism is usually categorized into five basic
modes: exon skipping of cassette exons, mutually exclu-
sive exons, alternative donor site, alternative acceptor
site, and intron retention. Exon skipping of cassette
exons is the most common mode in mammalian pre-
mRNAs, and it occurs when an exon is spliced out of
the primary transcript or retained. In some cases, multi-
p l ec a s s e t t ee x o n sa r em u t u a l l ye x c l u s i v e ,p r o d u c i n g
mRNA that always includes only one of several exon
choices. Defects in the AS mechanism have been
involved in many diseases [9-11]. Exon array technology
is a new type of microarray offering a more fine-grained
chip to support global inference about gene expression
at the level of individual isoforms and exons. It allows a
more comprehensive analysis of the transcriptome, as
well as the study of Alternative Splicing. One of the first
uses of the Affymetrix GeneChip Human Exon 1.0 ST
array [12] was the study of the aberrant splice variants
involved in the initiation and/or progression of glial
brain tumor [13]. Numerous studies followed, including
amyotrophic lateral sclerosis and multifocal motor neu-
ropathy [14], cystic fibrosis and several human cancers
[15,16].
Exon arrays are one of the first available chips to sur-
vey both gene expression and AS patterns on the whole-
genome scale on a single array. One exon array is a chip
containing about 5.4 million probes grouped in 1.4 mil-
lion probesets, each one designed to map at most a sin-
gle exon. Probesets are grouped into transcript clusters
that are portions of the genome roughly corresponding
to genes.
The output of an Affymetrix Exon Array is a binary
CEL file containing probe level intensities from a single
array. Affymetrix offers a toolbox essential for CEL files
analysis, the Affymetrix Power Tools (APT) [17], and a
set of library files with information useful for the prepro-
cessing of raw data and the annotation of probesets and
transcript clusters. Using APT, we extract numerical
expression intensities for each probeset (called “exon
level” expression), a summarization of transcript cluster
expression intensity computed from its probesets (“gene
level” expression), a quality assessment of each probeset
value (DABG: Detection Above BackGround [18]) and a
statistical value for the AS detection (MiDAS: Microarray
Detection of Alternative Splicing [19]). For the analysis of
AS events in the comparison between normal and patho-
logical tissues, Affymetrix suggests as a standard analysis
his MiDAS and classical t-test statistics. The evaluation
of the AS trend is computed by the Splicing Index, a
ratio between normal and pathological exon expression,
each of them normalized on the overall gene level
expression.
Other statistical algorithms, such as MADS [20] and
FIRMA [21], have also been proposed. These methods
focus their analysis on statistical computations, providing
the users with command-line applications and requiring
prior knowledge of statistical programming languages
like R. AltAnalyze [22], easyExon [23] and Exon Array
Analyzer [24] are the most recent tools for exon array
analysis. AltAnalyze, when installed with DomainGraph
plug-in of CytoScape, is a complex software workflow for
the statistical and visual analysis of exon expression data,
and it requires a minimum of 1 GB of RAM and from 1
up to 3 GB free hard-drive space for species gene data-
bases, Affymetrix libraries and annotation files. Another
stand-alone software is the java-based easyExon, which
offers fewer facilities, as it provides expression statistics
results with only a few biological annotations such as
gene and GO annotations for probesets. Exon Array Ana-
lyzer is a web tool that allows the user to upload his CEL
files and shows tabular exon and gene level expression
results, together with MiDAS and FIRMA output.
The heaviest drawback of stand-alone software
packages for exon array analysis is the huge requirement
in RAM and hard disk space. They ensure privacy of data
but they need an expensive setup and advanced program-
ming skills for a flexible analysis. The available web tools,
f o rt h e i rp a r t ,a r en o tv e r yc o m p l e t ea st h e yl a c ki n
advanced analysis instruments. The most important limit
of all the existing tools providing a graphical interface is
forcing the user to input also some analysis parameters
such as p-value thresholds and AS extraction algorithm
option during the upload of CEL files. It means that the
user must choose his analysis parameters even when he
does not know how they will influence the results, and
even if he wants to change just one parameter, he must
restart the entire analysis process.
The aim of BEAT, the platform we describe in this
paper, is to provide the scientific community with a
user-friendly platform to analyze exon array datasets
with rigorous statistical methods and an easy-to-use gra-
phical user front-end. BEAT has been developed as a
web tool because we think that the Internet is the most
important means for spreading research results, using
only a browser and the Internet connection (today even
o nm o b i l ep h o n e s ) .A tt h es a m et i m ew ep u ta t t e n t i o n
on the security and privacy of data and result transfer.
BEAT simplifies the exon array analysis workflow asking
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interactive plots and tables. Furthermore, it introduces
some new instruments to obtain very useful and easily
interpretable results for each case study, such as the
novel use of meta statistics and the possibility to exploit
other clinical information about the patients for a multi-
variate analysis of exon expression intensities.
Implementation
Architecture of the platform
A top-level view of BEAT has the same structure of a
classical web application, since the platform was
designed according to the typical three tier architecture.
This approach allows a modular, scalable, extensible,
and easily administrable system architecture, in order to
guarantee the interoperability among the components.
1. Data. The first tier consists of a data warehouse.
The data warehouse stores all data sources and sta-
tistical processed data allowing smart data storing
and efficient data retrieving. It consists of more than
one relational database, a repository/staging area and
data marts. It is described in detail in the “Data
Warehouse” section and in the Additional file 1.
2. Service-integration. The second tier consists of
an application server (Tomcat) dedicated to the
deployment of the web interface and a set of appli-
cations. Such applications perform both exon and
gene level analysis through the APT and the statis-
tics and meta statistics using complex R routines, as
described in the “Analysis workflow” section.
3. Web front-end. The third tier consists of the web
query interface, which is developed for displaying
the analysis results and browsing the data contained
in the Data Warehouse, in order to provide interac-
tive plots and a flexible and advanced query system.
Figure 1 represents the graphical schema for the archi-
tecture of BEAT.
From the user perspective, the platform is designed to
analyze a user “case study” in a workflow that starts
from a set of Affymetrix exon array experiment output
files (CEL files) and ends with the visualization of the
statistical analyses of gene differential expressions and
exon splice variants.
Data sources
The data sources used by BEAT are stored as relational
tables in the data-warehouse component and they can
be classified in different types:
- User data file: the outputs of Affymetrix Exon
Array experiments (CEL files), which are binary files
containing probe-level intensities from a single array;
a text file filled by the user through a web wizard
containing metadata for each CEL file, including
medical record information about a patient, such as
gender, age of disease onset, tumor type and tissue,
etc. These files are interpreted and elaborated by
Affymetrix APT tools.
- Affymetrix annotation files: text files contain
both design-time information and NetAffx [25] map-
ping between probesets and public mRNA sequences
(cDNAs). These annotations include statistical infor-
mation specific to the probeset composition and
sequence annotations at both exon and transcript
level extracted from public databases. In the plat-
form we have used the Relese29 - hg18 version.
- Public database: different public biological data-
bases stored in the data warehouse come from struc-
tured and unstructured sources like external
database dump or text/CSV files. They are: HUGO
Gene Nomenclature Committee (HGNC) database
[26] reporting information about official human
gene names and aliases; KEGG [27], BioCyc [28] and
BioCarta Pathways [29] for the association among
genes and biological pathways involved; Gene Ontol-
ogy (GO) database [30], that provides a controlled
vocabulary of terms which describe gene product
characteristics and gene product annotation data.
- Specialized database: ASPicDB [31], a database
designed to provide information and reliable annota-
tions of the AS pattern of human genes; FeatDB, a
custom database reporting chromosomal location
about known (RefSeq) human transcripts extracted
from UCSC genome browser [32].
Analysis workflow
Figure 2 shows the analysis workflow for the entire
bioinformatics process performed on Affymetrix Exon
Array datasets. The first steps involve CEL file prepro-
cessing using APT. Starting from raw binary CEL file
we extract probeset and transcript cluster expression
intensities performing a Robust Multi-chip Analysis
(RMA) summarization. All the other statistical computa-
tions are performed using R [33].
Each probeset is designed to map only one exon or a
part of it and it can be used for the exon level analysis.
The transcript cluster represents groups of transcripts
falling in the same portion of a chromosome. These
summarization expression values are used for the exon
level analysis, because values of the same probeset com-
ing from different CEL files can be compared normaliz-
ing them on their transcript cluster expression.
The transcript cluster values are not very accurate
metrics for gene level analysis, because they often group
together different genes sharing only a few probesets,
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son, we have slightly modified RMA parameters in order
to obtain a more correct gene expression profile, com-
puting the expression of each gene using only the pro-
besets mapped to its known isoforms.
Unlike the other existing Exon Array tools, in our
workflow the exon level and the gene level results
merge into the use of meta statistics that are introduced
to evaluate the results and to explore the data. The fol-
lowing paragraphs describe all these steps in detail.
Exon level analysis
In exon level analysis, the normalized probeset expres-
sion intensities are used to study changes in exon
expression when comparing two or more experimental
groups in order to find out the AS events correlated to
the groups.
The most common studies compare normal to patho-
logical tissues. For this type of analysis in which only
one variable is involved, we perform all the standard
statistics on each probeset: the Splicing Index (logarith-
mic ratio between normal and pathological normalized
exon expression), useful to evaluate the trend of the
expression changes; the Student’s t-test; the MiDAS, the
Affymetrix algorithm to extract the p-value. We also
compute the Fold Change on probeset intensities not
normalized for the overall gene expression level.
For a deeper analysis of the AS events, we provide
alternative isoforms of the gene under investigation, for
both known and predicted alternative transcripts.
In order to perform a quality estimation of each statis-
tical result obtained at exon level, we allow the user to
filter data according to the Affymetrix DABG p-value
estimation.
Multivariate AS analysis
Another interesting study in Alternative Splicing is mul-
tivariate analysis, in which AS events are evaluated in
relation to more than one clinical variable, such as gen-
der, stage of the pathology or age of disease onset.
Figure 1 Architecture of the BEAT platform. BEAT was designed using a typical three tier architecture. The first tier consists of a data
warehouse, which stores all data sources and statistical processed data allowing smart data storing and efficient data retrieving. The Service-
integration tier consists of a Tomcat application server and a set of applications performing exon and gene level analysis. The web front-end tier
is the query interface, with its advanced query system and interactive plots.
Consiglio et al. BMC Bioinformatics 2012, 13(Suppl 4):S21
http://www.biomedcentral.com/bmcbioinformatics/supplements/13/S4/S21
Page 4 of 14Affymetrix proposes the use of ANOVA [34], which is
widely used by biologists and clinicians in several
experiments as prognostic significance of tumor states.
In exon array experiments the multivariate analysis is
often set aside, mainly because of the lack of data on
CEL files variables other than normal-pathological infor-
mation and the complexity of repeating the ANOVA
test and its p-value correction on thousands of probesets
at the same time.
In our platform, we have included a component for
multivariate analysis that simplifies the application of
ANOVA, providing an easily interpretable output of the
multivariate analysis. The methodology is based on a
well-known data mining paradigm: the Decision Tree
Algorithm [35,36]. In order to manage both numerical
and symbolic data, we use a conditional inference deci-
sion tree [37], training it on normalized expression
intensities. Conditional inference trees estimate a regres-
sion relationship by binary recursive partitioning in a
conditional inference framework. Roughly speaking, the
algorithm works recursively repeating the following
steps: it tests the global null hypothesis of independence
among any of the input variables and the response; it
s t o p si ft h i sh y p o t h e s i sc a n n o tb er e j e c t e d ,o t h e r w i s ei t
selects the input variable with the strongest association
to the response, measured by a p-value corresponding
to a test for the partial null hypothesis of a single input
variable and the response; it implements a split in the
selected input variable. The implementation uses a uni-
fied framework for conditional inference, or permutation
tests [38].
The output of the algorithm is a tree graph in which
each node is a variable that influences the changes in
expression intensities. If the variable is binary, the node
splits the data according to its two values, while if the
variable is numerical, the node indicates a threshold cor-
related to a significant change in expression intensity.
The rules for the generation of nodes and for the prun-
ing of the tree are based on ANOVA.
For example, if expression signal of a probeset reveals
a correlation both to Male/Female comparison and to a
threshold of 60 as age of disease onset value, the tree
highlights in its output the two variables and the thresh-
old, suggesting to the user AS events correlated to non
pathological characteristics.
Gene level analysis
Gene expression intensities are summarization values
computed from probeset intensities. In order to evaluate
the changes in gene expression profile, we compute the
Fold Change ratio to compare normal to pathological
issues, validated by means of the t-test p-value.
T h eg e n el e v e lv a l u ei sn o tav e r yi n f o r m a t i v ei n d e x
in the AS events discovery, as it characterizes the
w h o l eg e n ed i f f e r e n t i a le x p r e s s i o n .W ei n t r o d u c et h e
Figure 2 BEAT analysis workflow. Elliptical boxes represent every type of data sources, blue rectangles represent processes and applications,
with differently colored arrows for input and output flow. Green boxes represent front-end result visualization. For graphical reason only, CEL
files and Medical Record input are duplicated for Exon and Gene processing.
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to obtain a method to compare genes having different
characteristics.
Meta statistics
Meta statistics are descriptive metrics used to provide
interpretable information describing the expression pro-
file of all probesets belonging to one gene. For example,
if a gene is subjected to an AS event, we will see a very
low p-value for the probesets involved in the AS, and
higher values for the unaltered probesets. In terms of
meta statistics, this can be represented with a minimum
p-value tending to 0 and a mean p-value tending to 1.
Therefore, the meta statistics are defined as minimum,
maximum, mean, and variance values, which are com-
puted on the standard exon level statistics results. The
default values of the search for AS events are given into
the search page of BEAT. Together with gene level
results, the meta statistics have been used with a sorting
algorithm in order to cluster together genes according
to their characteristics.
This method has been borrowed from the application
of clustering algorithm as used in many bioinformatics
approaches. When we have to process a huge number
of data, it is often useful to group the ones with similar
characteristics into clusters. Similarity is evaluated by
means of a distance metric. Our idea was to exploit
such a distance metric to extract genes with specific
characteristics, i.e. choosing the center of the cluster
and analyzing the nearest genes. Meta statistics have
been designed to be used for this type of distance com-
parison, and the distance metrics used is the Euclidean
distance with variables scaling, because it allows a very
quick distance computation for thousands of multi-
dimensional points [39].
Meta statistics and the sorting by Euclidean distance
have been applied in the BEAT platform both to opti-
mize the search tools provided for result exploration
and to analyze the expression profile of genes belonging
to the same pathway or mapped to the same Gene
Ontology term.
The Data Warehouse
The data management in BEAT is delegated to a data
warehouse (DW). A DW is defined as “a subject-oriented,
integrated, non-volatile and time-variant collection of
data in support of management’s decisions” [40]. The
data in the warehouse are filtered, aggregated and stored
in smaller data storages, usually called data marts (DM),
properly designed for specialised purposes. A DW is fre-
quently used in business applications but in the last years
it is often used also in the biomedical (especially clinical)
domain [41-44]. The choice of a DW for BEAT data
management was driven by the following aspects:
- The DW is a consolidated database technique, sui-
table for storing the large quantity of experimental
data produced by exon array experiments. A single
case study produces 1.4 million probeset signals for
each chip (stored as records in a database table) and
the same number of results for each statistical analy-
sis performed on these signals.
- The DW architecture facilitates integration of
locally produced experimental data with public
bioinformatics databases used as functional annota-
tion extensions (the biological background knowl-
edge), with the aim of easily producing new
knowledge.
- A DW allows multidimensional On Line Analytical
Processing (OLAP) techniques to support data
mining, statistical analyses and reporting functional-
ities that are normally not feasible with typical trans-
actional databases approaches (OLTP). The OLAP
functionality adapts well to the complex analytical
procedures implemented in this tool.
BEAT DW complies a three-tier architecture. The sta-
tistical analysis design implemented in BEAT has led to
the definition of two data marts (BEAT_exp_exonlevel
and BEAT_exp_genelevel)t h a ts u p p o r tt h ea n a l y t i c a l
processes of the exon and gene level analyses described
in the previous section. In addition, a repository was
implemented (named BEAT_Repository), where the
input data sources (see “Data Sources” paragraph) are
stored, processed, homogenized, and reconciled in order
to facilitate the data mart population.
The physical tables belonging to the data marts and
the repository have been populated through the use of
an Extract/Transformation/Load (ETL) tool usually used
for this purpose in DW systems.
For the development of the DW we used MySQL Rel.
5.× and Infobright [45] ICE 4.0 (a column-oriented rela-
tional database engine integrated with MySQL dedicated
to DW system) Relational Database Management Sys-
tems (RDBMS), while to implement the ETL process we
used the open source tool Pentaho Data Integration
(aka Kettle [46]), a component of the Pentaho Open
Source Business Intelligence.
The data marts were designed using the fact constella-
tion schema conceptual model and adopting the stan-
dard Dimensional Fact Model graphical annotation [47].
Supplementary information about the repository and
the data marts can be found in Additional file 1.
System deployment process
In BEAT, the analysis of a user case study corresponds
to an execution of a pipeline process to deploy all data
transformation and statistical analyses performed by
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data (exon array CEL files). The entire process of setup,
initialization, deployment and commissioning of a case
study is described by the BEAT Deploy System Lifecycle
Business Process Diagram shown in Figure 3. It is struc-
tured in a hierarchical way where each block can be
blown-up in sub-diagrams. The process diagram is com-
posed by the following macro steps:
1. Data source input process. It is the process dele-
gated to extract all the data sources needed by a
case study: CEL files, medical record file, Affymetrix
Exon array annotation files and all the public and
specialized database listed in the “Data Sources”
paragraph. The files and database extracted are used
by the ETL process to populate the repository and
data marts (Figure 3-a).
2. S e t u pf i l es y s t e me n v i r o n m e n tp r o c e s s .T h i s
process initializes all the environment variables and
creates the directory tree that will contain all input
and processed case study files (Figure 3-b1).
3. Setup DB environment process. This process
creates the new two empty BEATdm_exp#_exonlevel
and BEATdm_exp#_genelevel data marts related to a
Figure 3 BEAT deploy system lifecycle business process diagram. UML diagram of BEAT system deploy process. Each box represents a
process, eventually composed by sub-processes, implemented by the Kettle ETL tool. The diagram emphasizes the logical sequence of processes
where the arrows represent the process flow. In the diagram, the main data flows involved in the system deploy process are also represented.
Consiglio et al. BMC Bioinformatics 2012, 13(Suppl 4):S21
http://www.biomedcentral.com/bmcbioinformatics/supplements/13/S4/S21
Page 7 of 14particular case study identified by the “#” id in the
CaseStudy metadata table (Figure 3-b2).
4. BEAT statistical application process. It manages
the statistics and meta statistics process analyses for
gene and exon level. It is composed by two sub-pro-
cesses: APT Process and R Process (see Figure 2).
The process starting from the input dataflow (CEL
files and medical records) produces the statistical
analysis files (Statistical DataOutput) that will popu-
late the fact tables of the data marts (Figure 3-c).
5. BEAT ETL system process. It contains all ETL
sub-processes that, starting from the input dataflow
(statistical analysis output files, medical record file and
data sources extracted by the first step), populate the
tables of the BEAT repository, BEAT_exp#_exonlevel
and BEAT_exp#_genelevel data marts (Figure 3-d).
The processes described in the BEAT Deploy System
Lifecycle Business Process Diagram have been imple-
mented by means of software components, named “job”
and “transformation”, using Kettle (described in “The
Data Warehouse” section). The whole process of input
data extraction, statistical analysis and data warehouse
population, is run by a single Kettle master job launched
by the BEAT system, after CEL files uploading. The
master job, where the right sequence of ETL compo-
nents is highlighted, is graphically presented in Figure 3.
The web front-end
BEAT provides an easy-to-use interface for the Affyme-
trix Exon Array datasets submission, a storage and
retrieval system, and interpretable outputs in terms of
figures and tabular data, using a web browser and the
Internet connection.
The platform has been developed using the Zkoss fra-
mework [48], which is a client-server Java-based tech-
nology. Zkoss shields from the complexities in classical
Ajax/Javascript approaches, focusing the developer on
the application logic, and delivering the user interfaces
within standard web browsers.
It runs on Apache Tomcat at the server side as a
cross-browser client engine responsible for the render-
ing of the front-end, which interacts with the application
server and handles events, communication and AJAX
duties. The client interface is also compatible with var-
ious mobile browsers.
The user interfaces are defined using a XML markup
language, and their functionalities can be extended with
embedded java code and/or integrated with many popu-
lar frameworks such as Spring, JasperRepors, Hibernate
and so on.
CEL files uploading
If the user wants to upload exon array files, he needs to
be registered with a valid e-mail address. Once logged
in, he can start the upload procedure that guides the
user in sending CEL files to the system. Clinical data
can be associated to each CEL file by filling a form: the
user must specify at least if the CEL file comes from
normal or pathological tissue and, if available, he can
add information about gender, age of onset of the
pathology, stage of the disease.
Once successfully loaded all the data, the user can set
the start of the analysis. CEL files and clinical data will
be preprocessed and analyzed, and the analysis results
will be loaded into the data warehouse. Once the pro-
cess is completed, the user will be notified by e-mail.
Each user is allowed to see only the results of his own
provided CEL files, unless these files have been marked
for public release during the upload phase.
In order to ensure the compliance with the national
laws and decisions from the Italian Data Protection
Authority, submitters are not allowed to provide any per-
sonal information (i.e. family/first name) and they can
only associate a numerical id with each CEL file, if they
need to create a link with their patient’s clinical record.
A daily backup of submitted data is performed, in order
to prevent data-loss on hardware faults. An important
aspect we have implemented in our case study creation
process is that the user is not asked to insert any analysis
parameters, such as p-value thresholds, or to choose the
AS extraction algorithm. In fact, the tool performs all the
standard analyses on the data and provides all the results,
showed using interactive plots and summary tables. All
private case studies will be deleted if they have not been
accessed for 18 months.
Once the automated analysis process performed on
the case study is completed, the user can explore the
results starting from the search page. The result visuali-
zation, in fact, is organized in just two steps: in the first
step we offer an advanced search tool to provide the
user with an intuitive and comprehensive way to search
through the data and to choose a list of interesting
genes; in the second step, the user can visualize all the
results of the analysis performed on a gene, at both
exon and gene level.
The search page
BEAT search page is a comprehensive instrument for
exploring the results of the analysis carried out on each
case study. As Figure 4 shows, it offers two main instru-
ments useful in the AS events mining: a search form for
retrieving genes with selected properties, and a set of sli-
ders for meta statistics values, provided to order data by
a selected statistical behavior. The activation of meta
statistics sorts the results according to the previously
described Euclidean distance. The exon level meta sta-
tistics, initialized with default values, help to find out
interesting AS events: the user has just to check all the
exon level meta statistics and start the search, to obtain
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events, sorted by relevance.
For example, if the user wants to investigate the
results of a particular gene, he can insert in the annota-
tion form one or more information useful to retrieve it
or if he wants to analyze all the gene with differential
expression belonging to a particular pathway, he can
select the pathway and order the data activating meta
statistics by inserting a high Fold Change Value and a
low t-test p-value. To search for isolated AS splicing
events in all genes belonging to chromosome 8, the user
can select the chromosome leaving start and stop posi-
tion blank, and exploit meta statistics to bring out data
with a low p-value for t-test and MiDAS and only one
Figure 4 Gene search page. This screenshot of the web front-end shows the page that allows the search through the data. Gene annotations
can be used to retrieve a list of examined genes (appearing as a table in the bottom of the page), while the meta statistics can be exploited to
order the rows of the result table.
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Page 9 of 14or two probesets revealing AS events. The search results
are visualized in a table with one gene by line satisfying
the search criteria, on the bottom of the page. Each row
of the table is linked to a page containing the detailed
results of the analyses carried out on the selected gene.
Gene result page
Each gene result page is composed by three sections, as
s h o w ni nF i g u r e5 .O nt h et o po ft h ep a g ew eh a v ea
summary of the information of the gene, such as name,
position on chromosome, Affymetrix identifications with
links to Affymetrix website, a list of pathways in which
the gene is involved and the Gene Ontology terms.
In the second section we show the exon level analysis
results and statistics about probeset expression intensi-
ties. For probeset normalized expression comparison
among experimental groups, we have chosen boxplot
representations, because they offer an intuitive visualiza-
tion of the distribution of data with identification of
outliers. The probesets that show a statistically signifi-
cant discrepancy in expression intensity are highlighted
in yellow. The second plot shows the trend of the Spli-
cing Index or Fold Change, showing positive peaks
where the normal data signal is higher than the patholo-
gical one, and negative peaks for the converse. AS index
values are drawn with a traffic light coloring that indi-
cates the p-value support of the data separation.
These plots are interactive and can be managed using
the button panel on the left. For example, it allows
applying DABG filter on the data used in the plots. We
can also choose experimental groups exploiting medical
Figure 5 Gene result page. The detail page for the analyses performed on a gene and its exons is composed by three sections. These sections
are highlighted with orange boxes and their content is detailed by the grey labels.
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Page 10 of 14record variables, in order to visualize boxplot separation
into user defined classes. To make a two class compari-
son (single variable analysis) we can choose the proper
AS index in the second plot. The parameters for the
classes (age, gender, stage) are not fixed: they are auto-
matically generated using supplementary information
entered during CEL file uploading.
In the second section we also report, aligned to their
portion of chromosome, the representation of probesets,
RefSeq isoforms and ASPiC predicted isoforms. These
images are useful for an immediate interpretation of AS
events, highlighted in the previous plots, and their possi-
ble influence on different isoforms.
A summary of all the evaluation carried out on each
probeset is given in a table. In the last column, we pro-
pose statistically significant class separations computed
by the conditional inference decision tree, with a button
that updates probeset expression plots applying the sug-
gested experimental groups.
I nt h el a s ts e c t i o no ft h eg e n ep a g ew eh a v et h e
results of the gene-level analysis and the values of the
meta statistics computed for the gene and for a cluster
containing genes belonging to the same pathway or
gene ontology.
Using a drop-down menu, the user can select a path-
w a yi nw h i c ht h eg e n ei si n v o l v e d .T h es y s t e ms h o w s
the other genes belonging to the same pathway, sorted
by Euclidean distance, so the genes that (statistically)
behave similarly to the gene under examination are
listed in the first rows.
We have the same table also for Gene Ontology
terms. Each gene name is a web link that opens its
detail page in a new window, to facilitate the compari-
son with the first gene examined.
Results
BEAT has been tested on two new datasets of exon
array experiments coming from colorectal cancer and
renal cell cancer experiments, produced at Medical
Genetics Unit of IRCCS Casa Sollievo della Sofferenza.
The Colorectal cancer dataset is composed by pairs of
normal and tumor colon specimens from 14 colorectal
cancer (CRC) patients undergoing curative resection at
the IRCCS Casa Sollievo della Sofferenza. None of the
patients suffered from hereditary CRC or had received
preoperative chemo-radiotherapy. The renal cell cancer
dataset is composed by pairs of normal and tumor renal
specimens from 13 renal cell carcinoma (RCC) patients.
All patients gave their informed consent to take part
in this study. The study was approved by the Hospital
Ethics Committee.
Both the datasets were profiled by the Affymetrix
H u m a nE x o n1 . 0S TA r r a y( 5 . 4m l np r o b e s ;1 . 4m l n
probesets) and anonymous information about gender,
age and cancer grading were collected from the medical
records of the patients.
In order to test the performances of the platform, we
have also uploaded a third case study containing 173
CEL files from colorectal cancer samples. This is a pub-
lic dataset and it has been downloaded from ArrayEx-
press (E-GEOD-24551).
The three case studies have been imported in BEAT
and their analysis results are publicly accessible and
allow the user to explore all the features of the platform.
Figure 6 shows the results on a gene known to be cor-
related to CRC, the solute carrier family 39 (zinc trans-
porter) member 14, SLC39A14 [49]. Probeset expression
plots reveal some evident AS events. In particular, we
can see an over-expression of probeset 5 (corresponding
to the fourth exon) and an under-expression of probe-
sets 6 and 7 (the fifth exon). This phenomenon repre-
sents the well-established case of mutually exclusive
exons for CRC tissues, and it is supported by opposite
peaks in Splicing Index and small p-values results.
Moreover, the AS event is also supported by the alterna-
tive transcripts in which the fourth and fifth exon never
co-occur.
Using the dropdown menu on the top right of the
page, the user can easily switch between all his “public”
or “private” case studies to monitor the different beha-
vior of a selected gene.
Discussion
Since the very first requirement analysis designed with
biologists and clinicians, it emerged that the main fea-
tures of the tool would have been ease of use and rapid
access to interpretable statistical analysis results.
We have kept in mind these requirements developing
a web application (paying attention to private data man-
agement) in which the user could perform each process
of his study through few steps. In the case study loading
procedure, for example, the user has only to upload his
CEL file and the available clinical information, while all
the other existent exon array tools ask for some analysis
parameters immediately after CEL file selection. For
instance, during the CEL file uploading in Exon Array
Analyzer (another existing web tool for exon arrays), the
user must define three sets of initial parameters: at first
he has to map each CEL to non intersecting groups,
then he has to define comparisons between coupled
groups, and at least he must choose some threshold for
the analysis algorithms. Then the analysis flow starts
and the initial parameters can be changed only restart-
ing the entire uploading procedure. Our analysis flow
does not require initial parameters because it is designed
to include all the statistical examinations. Threshold
values can be chosen from the user when visualizing the
final interactive plots, in order to see how the results
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Page 11 of 14change when varying the thresholds without reiterating
all the analysis workflow.
A quick access to all the data is enabled by the data
warehouse architecture underlying the tool. It integrates
pre-calculation steps exploiting the use of data marts
and fact tables. A comprehensive search page is pro-
v i d e dt oh e l pt h eu s e rr e t r i e v i n gt h em o s ti m p o r t a n t
analysis results. All the other tools working with exon
array lack in this feature; EAA, for instance, allows the
user to search through the data only by gene symbol
and by platform dependent identifiers defined by
Affymetrix.
Finally, the architecture of BEAT has been conceived
to manage scalability of data and analysis tools. Data
Figure 6 SLC39A14 example. This screenshot is the “exon level” section of the result page for SLC39A14 gene. Probeset boxplots highlighted in
yellow are aligned to red peaks in the Splicing Index. Alternative transcript representation displays that exons mapped to probesets 5 and 6-7
are mutually exclusive probesets.
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warehouse, in which each case study is stored in inde-
pendent data marts and the system performances are
not influenced by the growth in size of the data
warehouse.
At the same time, the analysis workflow design allows
an easy inclusion of new statistical tools that could
became standard in exon array experiments.
Conclusions
With the progress of massive production of biological
data, the bioinformatics community has to deal with a
growing need of easy-to-use applications for managing a
huge number of data.
BEAT provides a user-friendly application for a compre-
hensive study of Affymetrix Exon array data about human
d i s e a s e s .I to f f e r su s e f u la n a l y s i st o o l sr e q u i r i n gn op r o -
gramming knowledge, and it shows the results with easily
interpretable and interactive tables and graphics. The ana-
lysis workflow provides rigorous statistical methods per-
formed on exon array data, and the results are stored in a
data warehouse to ensure the optimization of the data
retrieval process. The introduction of meta statistics offers
a novel means of exploring results through a set of metrics
that summarize gene and exon level expression statistics.
AS events can be studied by comparing normal to patho-
logical tissues and by performing a multivariate analysis
on available medical record information, allowing biolo-
gists and clinicians to investigate changes in splicing pat-
terns from a wider point of view.
The architecture chosen for the development of BEAT
allows the improving of the platform with additional fea-
tures and with a minimum programming effort. Some
future developments are: integrating new statistical meth-
ods for AS analysis (like FIRMA); improving gene level
analysis, in order to allow comparisons between exon
arrays and microarrays results; extending the analyses to
other exon array platforms and organisms.
Availability and requirements
BEAT is a web platform and it is freely accessible at
http://beat.ba.itb.cnr.it.
The application has been tested with the latest ver-
sions of the following Internet browsers: Firefox 7,
Chrome 14, Internet Explorer 9, Safari 5, Opera 11.
Additional material
Additional file 1: PDF file containing supplementary documentation
about the data warehouse. In particular, we report a more detailed
description of the repository and data marts, and four tables with a
detailed description of fact tables, hierarchies and dimensional tables.
List of abbreviations used
APT: Affymetrix Power Tools; AS: Alternative Splicing; BEAT: Bioinformatics
Exon Array Tool; CEL: Affymetrix Exon Array output file extension; CRC:
colorectal cancer; DB: Data Base; DM: Data Mart; DW: Data Warehouse; ETL:
Extraction, Transformation, Loading; R: is a language and environment for
statistical computing and graphics; RCC: renal cell carcinoma; RMA: Robust
Multi-chip Analysis.
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